PDF(Pubmed)
Abstract：
Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient\'s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.
摘要：
胃癌（GC）是全球癌症相关死亡的第三大原因。由于缺乏特定症状和缺乏筛查计划，大多数患者被诊断为疾病的晚期/转移阶段。尤其是在西方国家。因此，尽管GC治疗机会有所改善，生存是令人失望的，最佳治疗的定义仍然是一个未满足的需求。在临床试验中开发了新的诊断技术，以表征GCs的遗传特征和新的潜在分子途径。如成纤维细胞生长因子受体（FGFR）途径，通过使用靶向治疗来提高患者的生存率。这篇综述的目的是总结FGFR信号在GC中的作用和影响，并概述在精准医学背景下，抗FGFR药物在GC治疗中的潜在有效性。
